• #AAN2018 – IONIS-HTTRx Shows Promise in Phase 1/2 Trial to Treat Early-stage Huntington’s
  • CHDI Foundation Joins PTC’s Quest to Develop Huntington’s Therapies
  • NIH Agency Pioneers Collaborative Research into Rare Diseases
  • HTT Mutations Seen to Cause Extensive Brain Remodeling, Affecting Motor and Cognitive Skills
  • Immunotherapy Candidates Showing Promise as Potential Ways of Treating Huntington’s
  • ‘Super Assassin’ of Cancer Cells Found in Huntington’s Disease Gene, Researchers Say
  • Targeting Enzyme to Reduce Mutant Protein Levels May Be New Strategy to Fight Huntington’s, Study Says
  • Huntington’s and ALS Nonprofits Partner with Teva to Discover New Therapeutic Targets
  • New Version of Genome Editing System Holds Potential to Treat Huntington’s
  • Genome Sequencing and Its Clinical Potential Focus of NYC Rare Disease Day Event
  • Strict Diet Control in Mouse Study Seen as Potential Huntington’s Disease Therapeutic Approach
  • ‘A Disease May Be Rare, Hope Should Never Be,’ Says Boy with SMARD at Connecticut Rare Disease Day Event